Esperion Therapeutics, Inc. announced today that President and CEO Dr. Roger Newton will be presenting at Windhover's 7^th Annual Therapeutic Area Partnerships Conference taking place on November 28-30, 2012 at the Westin Copley Place in Boston, MA.

"I am delighted that Windhover has recognized our company and provided us the opportunity to spotlight ETC-1002, a novel regulator of imbalances in carbohydrate and lipid metabolism as well as inflammation, at the upcoming 7th Annual Therapeutic Area Partnerships Conference."

"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees considered the most attractive opportunities the industry has to offer," said David Cassak, Vice President, Content, Windhover Conferences, a division of Elsevier Business Intelligence.  "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability."

The criteria for the top 10 were:

* Large market, large unmet need, with increasing opportunity
* History of the molecule and drug
* Strong science
* Strong company
* Diversity of indications
* Potential for new opportunities beyond the initial indications
* Multi-level partnering opportunities, i.e., biotech to biotech as well as pharma to biotech

Dr. Newton will be presenting an overview of Esperion's lead compound ETC-1002, a once-daily, oral drug, which has completed a 12-week, Phase 2 Lipid POC study and has demonstrated "statin-like" reductions in LDL-C.  Through regulation of AMP Kinase and ATP-citrate lyase, ETC-1002 has unique potential to beneficially alter several, relevant cardio-metabolic risk factors, including: Dyslipidemia, Glucose/Insulin, Inflammation and Blood Pressure.